Edwin Rock
CIK 1945417 · Chief Medical Officer · last filed 2024-06-24
Edwin Rock is a Chief Medical Officer who has filed 7 SEC Form 4 insider transactions across 1 company since 2022. The most recent filing shows the insider bought $78.8K of GLYC on Jun 24, 2024. Across all open-market trades the lifetime net is +$725.6K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
7
$725.6K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Chief Medical Officer | 680,403 | $15.70 | $10.68M | $725.6K | 7 | 2024-06-24 |
Recent Filings
7 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-24 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +305,000 | $78.8K | EDGAR |
| 2024-01-17 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-09-25 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +65,403 | $90.3K | EDGAR |
| 2023-01-20 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-12-27 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +110,000 | $247.5K | EDGAR |
| 2022-11-16 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +200,000 | $309.0K | EDGAR |
| 2022-09-07 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |